Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Elia Lima-Walton, MD
About the author:
Elia Suzette Lima-Walton, MD is part of the Elsevier Content Transformation & Health Analytics team in her role as a Clinical Knowledge Representation Specialist. She applies her clinical knowledge and analytics experience to support clinical ontologies, Smart Content applications, precision medicine, clinical decision support and inference products.
Elia went to medical school at Universidad Autónoma de Guadalajara in Mexico and completed her medical studies at New York Medical College.
Posts by Elia Lima-Walton, MD
Posted on April 26th, 2019 in Pharma R&D
In recent years, robotics, AI, and Machine Intelligence have been at the forefront of the symbiotic need for humans and our own AI technology to work together. Last year, ground breaking research by molecular chemists at Arizona State University has taken cancer research and treatment to a new level. They are in the process of developing an “origami-inspired” system that can identify the tumor, attack, and deploy a mechanism to suffocate the tumor. Innovation is everywhere in this field, and this one is truly amazing.(more…)
Posted on April 18th, 2019 in Pharma R&D
Elseiver’s Elia Lima-Watson, MD explores the phenomenon of automation int he lab beyond just rote tasks. Fascinating developments in this field and others continue to accelerate the discovery process at a dizzying rate.(more…)
Posted on March 28th, 2019 in Pharma R&D
Many biologic drugs with household names like Humira, Enbrel and Neulasta are protein-based drugs derived from living organisms that treat a wide range of diseases. While deliver complications have typically been administered via injection, there is an increasing trend in the Pharma R&D community to experiment with oral biologics, or an injection in pill form.(more…)